Investor's Business Daily on MSN4h
Amgen Shrugs Off A Surprise Setback For One Of Its Obesity Drugs
Amgen stock rose early Wednesday, though the biotech behemoth said the FDA placed one of its obesity treatments on clinical ...
Regeneron Is Playing Defense With Capital Allocation
Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...
Biotech Stock Roundup: REGN Up on Q4 Results, VRTX, AXSM Gain on Drug Approval
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.CTQLEHs_.js ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter 2024 Earnings Conference Call. My name is Tawanda, and I will be your ...
Regeneron Presents An Opportunity After LIBTAYO Sales Growth Bolsters Earnings
Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...
Regeneron Pharmaceuticals, Inc. (REGN) Stock Forecasts
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, ...
Regeneron Pharmaceuticals Inc (REGN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ...
Regeneron Pharmaceuticals Inc (REGN) reports robust financial performance with a 10% revenue increase and unveils new ...